On July 11, 2023, Hybio Pharmaceutical (Wuhan) Co., Ltd. (hereinafter referred to as "Hybio Wuhan"), a wholly-owned subsidiary of Shenzhen Hybio Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Hybio Pharmaceutical"), received the Approval Notice for Marketing Application of Chemical Active Pharmaceutical Ingredient (Acceptance No.: CYHS2260223) issued by the National Medical Products Administration (NMPA) for its Cetrorelix Acetate API, and the relevant information has been publicized on the official website of the Center for Drug Evaluation (CDE) under the NMPA. We hereby announce the relevant details as follows:
I. Registration Information of the API
Generic Name: Cetrorelix Acetate
Registration No.: Y20220000234
Packaging Specifications: 1g/bag; 2g/bag; 5g/bag; 10g/bag; 15g/bag; 20g/bag; 50g/bag
Manufacturer: Hybio Pharmaceutical (Wuhan) Co., Ltd.
Application Item: Marketing application for domestically manufactured chemical API and joint review with its finished dosage forms
Result: A (Approved for use in marketed finished dosage forms)
II. Other Information about the Drug
Cetrorelix Acetate is a synthetic decapeptide, whose finished dosage form is an injectable gonadotropin-releasing hormone (GnRH) antagonist, indicated for assisted reproduction and the inhibition of premature luteinizing hormone (LH) surge.












